Supernus Pharmaceuticals Inc
NASDAQ:SUPN

Watchlist Manager
Supernus Pharmaceuticals Inc Logo
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Watchlist
Price: 36.22 USD 1.12% Market Closed
Market Cap: 2B USD
Have any thoughts about
Supernus Pharmaceuticals Inc?
Write Note

Supernus Pharmaceuticals Inc
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Supernus Pharmaceuticals Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Research & Development
-$103.5m
CAGR 3-Years
-6%
CAGR 5-Years
-6%
CAGR 10-Years
-18%
Johnson & Johnson
NYSE:JNJ
Research & Development
-$16.4B
CAGR 3-Years
-5%
CAGR 5-Years
-8%
CAGR 10-Years
-7%
Bristol-Myers Squibb Co
NYSE:BMY
Research & Development
-$9.5B
CAGR 3-Years
1%
CAGR 5-Years
-13%
CAGR 10-Years
-10%
Pfizer Inc
NYSE:PFE
Research & Development
-$10.5B
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
-4%
Merck & Co Inc
NYSE:MRK
Research & Development
-$16B
CAGR 3-Years
-17%
CAGR 5-Years
-13%
CAGR 10-Years
-9%
Eli Lilly and Co
NYSE:LLY
Research & Development
-$10.5B
CAGR 3-Years
-15%
CAGR 5-Years
-14%
CAGR 10-Years
-8%
No Stocks Found

Supernus Pharmaceuticals Inc
Glance View

Market Cap
2B USD
Industry
Pharmaceuticals

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. The company is headquartered in Rockville, Maryland and currently employs 575 full-time employees. The company went IPO on 2010-12-28. The firm is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes treatments for epilepsy, migraine, hypomobility in Parkinson’s Disease (PD), cervical dystonia, and chronic sialorrhea. Its commercial portfolio of products includes Trokendi XR (topiramate) and Oxtellar XR (oxcarbazepine) for the treatment of epilepsy. Its APOKYN (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility in patients with advanced parkinson’s disease (PD). Its XADAGO (safinamide) is a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD. Its MYOBLOC (rimabotulinumtoxinB) is a product indicated for the treatment of cervical dystonia and sialorrhea in adults. Its pipeline of CNS product candidates includes SPN-812, SPN-817, SPN-820, SPN-830 and MYOBLOC.

SUPN Intrinsic Value
38.06 USD
Undervaluation 5%
Intrinsic Value
Price

See Also

What is Supernus Pharmaceuticals Inc's Research & Development?
Research & Development
-103.5m USD

Based on the financial report for Sep 30, 2024, Supernus Pharmaceuticals Inc's Research & Development amounts to -103.5m USD.

What is Supernus Pharmaceuticals Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-18%

Over the last year, the Research & Development growth was -20%. The average annual Research & Development growth rates for Supernus Pharmaceuticals Inc have been -6% over the past three years , -6% over the past five years , and -18% over the past ten years .

Back to Top